evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,166 questions · 1,249 findings · 76 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 378 · 30.3%GRADE not reported 61 · 4.9%Very low 377 · 30.2%Low 284 · 22.7%Moderate 120 · 9.6%High 29 · 2.3%

Summary of findings. Below‐elbow vs above‐elbow cast

'Treatment failure': secondary procedures such as remanipulation for early loss of position (only data for this used here); and change in treatment ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…

It is very uncertain whether summary of findings. Below‐elbow changes 'Treatment failure': secondary procedures such as remanipulation for… compared with above‐elbow cast (very low certainty).

1 finding from 1 review

Summary of findings. Below‐elbow vs above‐elbow cast

Minor complications (less serious).j Here represented by referral for physical therapy for range of motion limitation (post‐immobilisation after 4 weeks) · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…

It is very uncertain whether summary of findings. Below‐elbow changes minor complications.,j,k Here represented by Referral for physical… compared with above‐elbow cast (very low certainty).

1 finding from 1 review

Summary of findings: Defibrotide vs no treatment

Incidence of hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in incidence of hepatic veno‐occlusive disease ( compared with no treatment (low certainty).

1 finding from 1 review

Summary of findings: Defibrotide vs no treatment

Overall survival ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).

1 finding from 1 review

Summary of findings: Defibrotide vs no treatment

All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review

Summary of findings: Defibrotide vs no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).

1 finding from 1 review

Summary of findings: Defibrotide vs no treatment

Frequency of adverse events ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

It is very uncertain whether summary of findings: Defibrotide changes frequency of adverse events ( compared with no treatment (very low certainty).

1 finding from 1 review